New research suggests that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional lifestyle plans.
Published data in a major medical journal demonstrates that while overweight individuals can lose a large proportion of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users buying these treatments must be cognizant of the risk of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass in about one and a half years.
Weighing Treatments
The research, which examined 37 of studies involving over 9,000 of patients, compared the results of GLP-1 agonists with other pills.
Scientists point out that people who shed pounds through diet and exercise usually see a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Experts suggest the way of the injections is key to understanding the accelerated weight return.
These medications imitate a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing the hormone levels far above than normal might result in the system to produce less of its own natural GLP-1, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' results in hunger is unsuppressed, making overeating a significant risk."
A Chronic Disease?
The NHS suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, given the likelihood of weight regain, the therapy is often life-long.
This perspective is reinforced by drug manufacturers, who say that the results "underscore the chronic character of excess weight," similar to managing conditions like diabetes.
User Experiences
Individuals who have stopped the jabs describe a powerful return of appetite.
"It felt as if a trigger that goes on and I was suddenly ravenous," described one woman.
This challenge is compounded if patients have not developed lasting dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Use is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are potent agents for weight loss, they are not a permanent fix and long-term success hinges on integrated lifestyle changes.
